1. Effects of statins on triglyceride metabolism. Am J Cardiol 1998; 81(4A):32B–5B.
2. , , , et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621–7.
3. Immune therapy for autoimmune diseases. Science 2004; 305:212–16.
4. , , , et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687–92.
5. , , , et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203:401–12.
6. , , , et al. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 2006; 178:140–8.
7. , , , et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420:78–84.
8. , , , et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197:725–33.
9. , , , . Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett 2002; 333:167–70.
10. , , , , Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J Immunol 2004; 172:1273–86.
11. , , , et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93:948–56.
12. , , , Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100:2671–9.
13. , , , et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003; 17:905–7.
14. , , , et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002; 59:990–7.
15. , , , et al. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 2005; 174:5630–5.
16. , , , Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399–402.
17. , , , et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes–a possible protective mechanism against atherothrombosis. Thromb Haemost 2000; 84:680–8.
18. , , , et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18:1671–8.
19. , Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995; 181:765–7.
20. , Costimulation: building an immunological synapse. Science 1999; 283:649–50.
21. , , Functional diversity of helper T lymphocytes. Nature 1996; 383:787–93.
22. , , , Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893–5.
23. , , Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992; 176:1355–64.
24. , , , Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998; 161:4437–46.
25. , , , , Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008; 180:6988–96.
26. , , Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J Immunol 2003; 170:2427–34.
27. , The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424–35.
28. , , , , , ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. J Immunol 1998; 161:5755–61.
29. , , , , Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a rho-dependent pathway. J Immunol 1999; 162:2964–73.
30. , , , , , ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J Immunol 2000; 165:3375–83.
31. , , , et al. Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling. FASEB J 2002; 16:1185–94.
32. , , , et al. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J Immunol 2002; 168:4087–94.
33. , , , Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51:682–9.
34. , , , Drug Insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol 2005; 1:106–12.
35. , , , , , [When and how do we treat our hypercholesterolemic patients?]. Aten Primaria 1999; 24:397–403.
36. , , , et al. An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS). Neurology 2003; 60:A84 (abstract).
37. , et al. ITN020AI Study Management Team, Spencer and Zamvil. A randomized double-blind controlled study of atorvastatin in patients with clinically isolated syndrome: the STAyCIS study. submitted.
38. , , , , Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol 2007; 20:281–5.
39. , , , , Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008; 71:1390–5.
40. , , Simvastatin inhibits IFN-gamma-induced CD40 gene expression by suppressing STAT-1alpha. J Leukoc Biol 2007; 82:436–47.
41. , Jr., , Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415–21.
42. , , , et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009; 72:1989–93.
43. , , , et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008; 3:e1928.
44. , , , et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 2010; 16:450–4.
45. , , , et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler 2010; 16:848–54.
46. , , , , , The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon? CNS Neurosci Ther 2010; 16:362–73.
47. , , , Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56:702–8.
48. , , , , Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105:967–76.
49. , , , , , Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127:1370–8.
50. , , , et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172:7144–53.
51. , , , et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13:935–43.
52. , , , et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006; 116:1037–44.
53. (4S). Lancet 1994; 344:1383–9.
54. , , , et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528–40.
55. . The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349–57.
56. , , , et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J Am Med Assoc 2004; 292:2585–90.
57. , , Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346:539–40.
58. , , , , , Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58:1333–7.
59. , , , , Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001; 56:931–3.